Valsartan and Amlodipine Improved Haematological and Biochemical Indices of Vildagliptin-treated Streptozotocin-induced Diabetic Rats

Valsartan and Amlodipine Improved Haematological and Biochemical Indices of Vildagliptin-treated Streptozotocin-induced Diabetic RatsBackground: Diabetes mellitus (DM) and hypertension often coexist in sufferers, which exacerbates the complications of DM.Also, the impacts of antihypertensive medications on the treatment outcomes of DM are not fully understood.Objectives: Our objective was to evaluate the effect of valsartan and amlodipine on the hematological and biochemical differentials of vildagliptin-treated streptozotocin-induced diabetic rats.Methods: DM was induced in male Wistar rats by a single intraperitoneal dose of streptozotocin (40 mg/kg body weight).The animals were grouped as non-diabetic rats (control), untreated diabetic rats, and diabetic rats treated with 5 mg/kg vildagliptin only, 5 mg/kg plus 30 mg/ kg of vildagliptin and valsartan, respectively, and 5 mg/kg plus 2.5 mg/kg of vildagliptin and amlodipine, respectively.Drugs were administered orally, and rats were treated daily for three weeks.Then, blood samples were collected for hematological and biochemical analyses. Results:The addition of amlodipine and valsartan as adjuncts to vildagliptin appeared to alter the evaluated differentials compared to vildagliptin treatment alone.Furthermore, the assessment of renal and liver functions, as well as the lipid profile, showed that treatment with valsartan as an adjunct improved the outcomes. Conclusion:Our findings therefore suggest that amlodipine and valsartan brought about significant alterations in the differentials of diabetic rats treated with vildagliptin.